Anaïs Schavgoulidze, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chretien, Sophie Godet, Lydia Montes, Cherel Brieuc, Ikhlef Souhila, Anne Vekkhof, Thomas Chalopin, Bohrane Slama, Laurent Frenzel, Emilie Chalayer, Helene Gardeney, Magaret Macro, Bruno Royer, Stephanie Harel, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Philippe Moreau, Thierry Facon, Jill Corre, Cyrille Hulin, Xavier Leleu. "Longitudinal assessments of minimal residual disease in high-risk patients from benefit phase 3 randomized Study of isatuximab plus lenalidomide and dexamethasone with bortezomib (Isa-VRd) versus isard in newly diagnosed transplant ineligible multiple myeloma. (IFM 2020-05)." Blood, 2025. doi:10.1182/blood-2025-497